You have 9 free searches left this month | to do more

dasatinib

Dasatinib is a drug used to treat Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Leukemia, and other conditions. Dasatinib is being actively studied in 66 studies and prior, has been studied in 113.

Top SponsorsTop SitesTop Investigators
Bristol-Myers SquibbLocal InstitutionStephen Spurgeon
National Cancer Institute (NCI)M D Anderson Cancer CenterAbhinav Deol
M.D. Anderson Cancer CenterCity of Hope Comprehensive Cancer CenterPhilip C. Amrein, M.D.
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
J
Dasatinib In Waldenström Macroglobulinemia
Recruiting
  • Waldenstrom Macroglobulinemia
  • DASATINIB
  • Dasatinib
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2022-03-22
Mar 22, 2022
S
Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP
Recruiting
  • Dasatinib
  • +2 more
  • Dasatinib
  • Shenzhen, Guangdong, China
    Xin Du
2022-03-15
Mar 15, 2022
M
Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia
Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
  • Dasatinib
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-01-19
Jan 19, 2022
B
Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib
Active, not recruiting
  • Multiple Indications Cancer
  • Dasatinib
  • Besancon, France
  • +5 more
2021-12-02
Dec 2, 2021
N
Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors - 2018
Completed
  • Solid Tumors
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-07
Apr 7, 2022
M
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia
  • +3 more
  • Dasatinib
  • Decitabine and Cedazuridine
  • Houston, Texas
    M D Anderson Cancer Center
2021-12-29
Dec 29, 2021
M
Dasatinib in Resectable Malignant Pleural Mesothelioma
Active, not recruiting
  • Malignant Pleural Mesothelioma
  • Dasatinib
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2022-02-25
Feb 25, 2022
G
Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia - 2016
Completed
  • Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
  • dasatinib
  • Valencia, Spain
    Hospital La Fe
2022-03-16
Mar 16, 2022
N
Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
Active, not recruiting
  • Metastatic Pancreatic Adenocarcinoma
  • +3 more
  • Dasatinib
  • +2 more
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
2021-12-15
Dec 15, 2021
S
The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients
Recruiting
  • Chronic Myeloid Leukemia in Chronic Phase
  • Shenzhen, Guangdong, China
    Shenzhen Second People's Hospital
2022-03-15
Mar 15, 2022
M
Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
Active, not recruiting
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
  • Dasatinib
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-05-05
May 5, 2021
U
Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR - 2020
Terminated
Has Results
  • Breast Neoplasms
  • Triple Negative Breast Neoplasms
  • Dasatinib
  • +2 more
  • Chicago, Illinois
  • +1 more
2022-01-31
Jan 31, 2022
N
Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body
Not yet recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • Metastatic Triple-Negative Breast Inflammatory Carcinoma
  • Dasatinib
  • Icosapent Ethyl
  • (no location specified)
2022-03-11
Mar 11, 2022
U
Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations - 2019
Terminated
  • Glioma
  • +2 more
  • Ann Arbor, Michigan
    University of Michigan Cancer Center
2021-10-12
Oct 12, 2021
C
Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
Active, not recruiting
  • EGFR Gene Mutation
  • Nonsmall Cell Lung Cancer
  • Washington, District of Columbia
  • +1 more
2022-01-09
Jan 9, 2022
M
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis - 2020
Completed
Has Results
  • Breast Cancer
  • Bone Metastases
  • Dasatinib
  • Zoledronic Acid
  • Chicago, Illinois
  • +2 more
2022-02-02
Feb 2, 2022
H
Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Active, not recruiting
  • Chronic Myelogenous Leukemia
  • Dasatinib
  • Amman, Jordan
  • +4 more
2022-01-17
Jan 17, 2022
O
Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia - 2018
Completed
Has Results
  • Refractory Chronic Lymphocytic Leukemia
  • +4 more
  • Dasatinib
  • +2 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
2021-03-15
Mar 15, 2021
L
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia
Recruiting
  • Acute Myeloid Leukemia
  • Lanzhou, Gansu, China
    The First Hospital of Lanzhou University
2021-10-07
Oct 7, 2021
N
Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma - 2021
Completed
  • Rhabdomyosarcoma
  • +2 more
  • Los Angeles, California
  • +1 more
2022-02-01
Feb 1, 2022
M
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
Active, not recruiting
  • Acute Lymphoblastic Leukemia
  • New York, New York
    Memorial Sloan Kettering Cancer Center
2021-07-23
Jul 23, 2021
U
Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma - 2020
Completed
Has Results
  • Pancreatic Cancer Metastatic
  • Gainesville, Florida
    UF Health Cancer Center
2020-12-03
Dec 3, 2020
I
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Active, not recruiting
  • Acute,Leukemia, Lymphoid
  • Dasatinib
  • +12 more
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
2021-02-08
Feb 8, 2021
F
A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL
Recruiting
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • +2 more
  • Dasatinib
  • Xi'an, Shaanxi, China
    First Affiliated Hospital of Xian Jiaotong University
2021-09-29
Sep 29, 2021
M
ABL001 + Dasatinib + Prednisone in BCR-ABL+ B-ALL or CML
Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • Chicago, Illinois
  • +5 more
2021-12-27
Dec 27, 2021